INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close
This article was originally published in Scrip
Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.
You may also be interested in...
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.